Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield?


Journal Article (Review)

Recent developments hallmark the progress in the understanding of tumor immunology and related therapeutic strategies. The administration of interleukin-2 (IL-2) to patients with cancer has shown that immune manipulation can mediate the regression of established cancers. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing against these antigens has opened new avenues for the development of active immunization of patients with cancer. However, an efficient immune response against tumor comprises an intricate molecular network still poorly understood. Only when the code governing immune responsiveness of cancer will be deciphered, new therapeutic strategies could be designed to fit biologically defined mechanisms of immune rejection of cancer. In this review, we propose that the mechanisms regulating tumor rejection in response to vaccination will be more efficiently identified by following the evolution of treatment induced events within the tumor microenvironment taking advantage of recently developed technological tools. As a model, we will discuss the observed immune response to tumor antigen -specific immunization and its relationship with the systemic administration of IL-2.

Full Text

Duke Authors

Cited Authors

  • Mocellin, S; Panelli, M; Wang, E; Rossi, CR; Marincola, FM

Published Date

  • November 2002

Published In

Volume / Issue

  • 88 / 6

Start / End Page

  • 437 - 444

PubMed ID

  • 12597134

Pubmed Central ID

  • 12597134

International Standard Serial Number (ISSN)

  • 0300-8916


  • eng

Conference Location

  • United States